Lorcaserin for weight management

Diabetes, Metabolic Syndrome and Obesity

Volumn 6, Issue , 2013, Pages 209-216

  Taylor, James R ^a   Dietrich, Eric ^a   Powell, Jason ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Diabetes; Lorcaserin; Obesity

Indexed keywords

DEXFENFLURAMINE; HEMOGLOBIN A1C; LORCASERIN; LOW DENSITY LIPOPROTEIN; METFORMIN; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SULFONYLUREA;

BACKACHE; BARIATRIC SURGERY; BODY MASS; BODY WEIGHT; CLINICAL TRIAL (TOPIC); CONSTIPATION; CONTROLLED RELEASE FORMULATION; DEPRESSION; DIET THERAPY; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HUMAN; HYPOGLYCEMIA; LIFESTYLE MODIFICATION; LOW DRUG DOSE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COMPLIANCE; PATIENT COUNSELING; QUALITY OF LIFE; QUESTIONNAIRE; RESPIRATORY TRACT DISEASE; REVIEW; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; VALVULAR HEART DISEASE; WAIST CIRCUMFERENCE; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 84879042475     PISSN: 11787007     EISSN: None     Source Type: Journal    
DOI: 10.2147/DMSO.S36276     Document Type: Review

References (28)

1. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults 1999-2010. JAMA. 2012;307:491-497.
2. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011. Available from: http://www.cdc.gov/diabetes/pubs/factsheet11.htm. Accessed May 17, 2013.
3. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DE. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010;8:29.
4. Kramer H, Cao G, Dugas L, Luke A, Cooper R, Durazio-Arvizu R. Increasing BMI and waist circumference and prevalence of obesity among adults with type 2 diabetes: the National Health and Nutrition Examination Surveys. J Diabetes Complications. 2010;24:368-374.
5. Eckel RH, Kahn SE, Ferrannini E, et al. Obesity and type 2 diabetes: what can be unified and what needs to be individualized? J Clin Endocrinol Metab. 2011;96:1654-1663.
6. Inzucchi SE, Nauck M, Bergenstal RM, et al; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-1379.
7. Ritter S, Vetter ML, Sarwer DB. Lifestyle modifications and surgical options in the treatment of patients with obesity and type 2 diabetes mellitus. Postgrad Med. 2012;1244:168-180.
8. Tuomilehto J, Lindstrom J, Eriksson JG, et al; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
9. Ilanne-Parikka P, Eriksson JG, Lindstrom J, et al; Finnish Diabetes Prevention Study Group. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care. 2008;31:805-807.
10. Ilanne-Parikka P, Laaksonen DE, Eriksson JG, et al. Leisure-time physical activity and the metabolic syndrome in the Finnish Diabetes Prevention Study. Diabetes Care. 2010;33:1610-1617.
11. Laaksonen DE, Lindstrom J, Tuomilehto J, Uusitupa M; Finnish Diabetes Prevention Study Group. Increased physical activity as a cornerstone in the prevention of type 2 diabetes in high-risk individuals. Diabetologia. 2007;50:2607-2608.
12. Wadden TA, Butryn ML, Wilson C. Lifestyle modification for the management of obesity. Gastroenterology. 2007;132:2226-2238.
13. Sarwer DB, von Sydow Green A, Vetter ML, Wadden TA. Behavorial therapy for obesity: where are we now? Curr Opin Endocrinol Diabetes Obes. 2009;16:347-352.
14. Perri MG, Corsica JA. Improving the maintenance of weight loss in behavioral treatment of obesity. In: Wadden TA, Stunkard AJ, editors. Handbook of Obesity Treatment. 1st ed. New York, NY: Guilford Press; 2002.
15. Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C. The FDA's assessment of two drugs for chronic weight management. N Engl J Med. 2012;367:1577-1579.
16. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial. Obesity. 2011;20:330-342.
17. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341-1352.
18. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95: 297-308.
19. US Food and Drug Administration. What is this new weight loss drug approved by the FDA? FDA Blogspot. Available from: http://fdabelviq.blogspot.com/. Accessed May 17, 2013.
20. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight-loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96:3067-3077.
21. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245-256.
22. O'Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity. 2012;20:1426-1436.
23. Belviq (lorcaserin hydrochloride) package insert. Zofingen, Switzerland: Arena Pharmaceuticals GmbH; 2012.
24. Flinn R, Edney A. Arena's Diet Pill May Spur Renewed Race From Drugmakers. Bloomberg. Retrieved from: http://www.bloomberg.com/news/2012-2006-28/arena-s-diet-pill-may-spur-renewed-race-from-drugmakers.html. Accessed May 17, 2013.
25. Fabricatore AN, Wadden TA, Moore RH, et al. Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis. Obes Rev. 2009;10:333-341.
26. Kolotkin RL, Thomas D. The Impact of Weight on Quality of Life-Lite (IWQOL-Lite). Office of Licensing and Ventures. Copyright 2013 Duke University. Available from: http://www.qualityoflifeconsulting.com/iwqol-lite.html. Accessed April 10, 2013.
27. Beck AT, Steer RA, Brown GK. Beck Depression Inventory®-II. Copyright © 2012 Pearson Education Inc. Available from: http://www.pearsonassessments.com/HAIWEB/Cultures/en-us/Productdetail.htm?Pid=015-8018-370. Accessed April 8, 2013.
28. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366:1567-1576.